Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Boys age ≥7 years with DMD confirmed clinically and by mutation analysis able to undergo cardiac magnetic resonance (CMR) without sedation~* LV EF ≥45% (+/-5%) by clinically-acquired echocardiography, nuclear scan or cardiac MRI done within 2 weeks of enrollment~Exclusion Criteria:~* Non-MR compatible implants~* Severe claustrophobia~* Gadolinium contrast allergy~* Kidney disease~* Prior use of or allergy to aldosterone antagonist~* Use of other investigational therapy.

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
- Spironolactone (Type: ACTIVE_COMPARATOR): Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.

Based on this trial design, predict the completion outcome and termination type (if applicable).